Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Race Oncology Ltd. ( (AU:RAC) ).
Racura Oncology Ltd has applied to the ASX for quotation of 16,620 new ordinary fully paid shares, to be issued on March 12, 2026, under its existing RAC ticker. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s free float and potentially enhancing liquidity for investors without materially altering its capital structure.
The move reflects standard capital management activity for an oncology-focused biotech and signals ongoing utilisation of equity-linked incentives previously granted to stakeholders. While the size of the issuance is relatively small in the context of typical market volumes, it incrementally broadens the company’s shareholder base and confirms continued compliance with ASX listing and quotation procedures.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australia-listed biotechnology company focused on oncology, with its ordinary fully paid shares trading on the ASX under the ticker RAC. The company operates in the cancer therapeutics sector, where access to capital markets via share quotation is critical for funding research, development, and potential commercialisation activities.
Average Trading Volume: 162,818
Technical Sentiment Signal: Buy
Current Market Cap: A$421.6M
See more insights into RAC stock on TipRanks’ Stock Analysis page.